If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Rezvoglar ™ (insulin glargine-aglr) injection
3 mL (100 units/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is Rezvoglar™ (insulin glargine-aglr) biosimilar to, and interchangeable with, Basaglar® (insulin glargine)?
Rezvoglar is not biosimilar to, or interchangeable with, Basaglar.
Rezvoglar and Interchangeability With Basaglar
Rezvoglar™ (insulin glargine-aglr) 100 units/mL is not approved as biosimilar to, or interchangeable with, Basaglar® (insulin glargine) 100 units/mL.1
Pharmacists cannot substitute Rezvoglar for Basaglar without a new prescription. Health care professionals will need to write a new prescription for Rezvoglar.
Rezvoglar is only approved as biosimilar to, and interchangeable with, its reference product, Lantus® (insulin glargine) 100 units/mL.1
Enclosed Prescribing Information
Reference
1Rezvoglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
Date of Last Review: November 07, 2022